Home LiteratureArticle Details
PMID: 10499922 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Viral dynamics of acute HIV-1 infection.

The Journal of experimental medicine ·Vol. 190 ·No. 6 ·1999-09-20 ·Pages 841-50

Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV

Abstract

Viral dynamics were intensively investigated in eight patients with acute HIV infection to define the earliest rates of change in plasma HIV RNA before and after the start of antiretroviral therapy. We report the first estimates of the basic reproductive number (R(0)), the number of cells infected by the progeny of an infected cell during its lifetime when target cells are not depleted. The mean initial viral doubling time was 10 h, and the peak of viremia occurred 21 d after reported HIV exposure. The spontaneous rate of decline (alpha) was highly variable among individuals. The phase 1 viral decay rate (delta(I) = 0.3/day) in subjects initiating potent antiretroviral therapy during acute HIV infection was similar to estimates from treated subjects with chronic HIV infection. The doubling time in two subjects who discontinued antiretroviral therapy was almost five times slower than during acute infection. The mean basic reproductive number (R(0)) of 19.3 during the logarithmic growth phase of primary HIV infection suggested that a vaccine or postexposure prophylaxis of at least 95% efficacy would be needed to extinguish productive viral infection in the absence of drug resistance or viral latency. These measurements provide a basis for comparison of vaccine and other strategies and support the validity of the simian immunodeficiency virus macaque model of acute HIV infection.

MeSH Terms
AIDS Vaccines/administration & dosage,immunology Acquired Immunodeficiency Syndrome/immunology,virology Adult Female HIV-1/physiology Humans Male Middle Aged Time Factors Viremia Virus Replication
Chemicals
AIDS Vaccines
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Little S J
Department of Medicine, University of California San Diego, San Diego, California 92103, USA. slittle@ucsd.edu
McLean A R
Spina C A
Richman D D
Havlir D V
References (34)
34 references, click to expand
  1. Cell-associated viral RNA expression during acute infection with HIV type 1.
    AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1141-9 PMID: 9737585
  2. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen.
    AIDS. 1998 Aug 20;12(12):1483-90 PMID: 9727569
  3. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
    Nat Med. 1999 May;5(5):512-7 PMID: 10229227
  4. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
    AIDS. 1999 Apr 16;13(6):677-83 PMID: 10397562
  5. The analysis of equilibrium in malaria.
    Trop Dis Bull. 1952 Sep;49(9):813-29 PMID: 12995455
  6. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion.
    Lancet. 1985 Mar 9;1(8428):537-40 PMID: 2857899
  7. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
    J Immunol. 1985 Nov;135(5):3151-62 PMID: 2995487
  8. Primary human T-lymphotropic virus type III infection.
    Ann Intern Med. 1985 Dec;103(6 ( Pt 1)):880-3 PMID: 2998251
  9. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.
    J Virol. 1989 Sep;63(9):3708-13 PMID: 2760980
  10. HIV-1 replication is controlled at the level of T cell activation and proviral integration.
    EMBO J. 1990 May;9(5):1551-60 PMID: 2184033
  11. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells.
    J Virol. 1990 Sep;64(9):4093-8 PMID: 2384914
  12. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals.
    Proc Natl Acad Sci U S A. 1990 Aug;87(16):6058-62 PMID: 2385584
  13. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
    N Engl J Med. 1991 Apr 4;324(14):954-60 PMID: 1900576
  14. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.
    N Engl J Med. 1991 Apr 4;324(14):961-4 PMID: 1823118
  15. Population dynamics of HIV within an individual after treatment with zidovudine.
    AIDS. 1991 May;5(5):485-9 PMID: 1677807
  16. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.
    N Engl J Med. 1993 Apr 22;328(16):1163-5 PMID: 8455683
  17. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.
    Ann Intern Med. 1995 Apr 15;122(8):573-9 PMID: 7887550
  18. Activation of virus replication after vaccination of HIV-1-infected individuals.
    J Exp Med. 1995 Dec 1;182(6):1727-37 PMID: 7500017
  19. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994.
    MMWR Morb Mortal Wkly Rep. 1995 Dec 22;44(50):929-33 PMID: 8531910
  20. Reduction of HIV concentration during acute infection: independence from a specific immune response.
    Science. 1996 Jan 26;271(5248):497-9 PMID: 8560262
  21. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Science. 1996 Mar 15;271(5255):1582-6 PMID: 8599114
  22. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
    Science. 1996 May 24;272(5265):1167-70 PMID: 8638160
  23. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.
    J Infect Dis. 1996 Jul;174(1):195-8 PMID: 8655994
  24. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
    JAMA. 1996 Jul 10;276(2):105-10 PMID: 8656501
  25. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro.
    J Clin Invest. 1997 Apr 1;99(7):1774-85 PMID: 9120023
  26. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    J Infect Dis. 1997 Jun;175(6):1502-6 PMID: 9180194
  27. Virus dynamics and drug therapy.
    Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6971-6 PMID: 9192676
  28. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.
    J Virol. 1997 Oct;71(10):7518-25 PMID: 9311831
  29. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
    Science. 1997 Nov 14;278(5341):1291-5 PMID: 9360926
  30. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Science. 1997 Nov 14;278(5341):1295-300 PMID: 9360927
  31. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
    Science. 1997 Nov 21;278(5342):1447-50 PMID: 9367954
  32. The care of persons with recent sexual exposure to HIV.
    Ann Intern Med. 1998 Feb 15;128(4):306-12 PMID: 9471935
  33. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention.
    MMWR Recomm Rep. 1998 May 15;47(RR-7):1-33 PMID: 9603630
  34. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1999-09-20
Pages
841-50
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2195636
Subset
IM
Grants
NIAID NIH HHS · R24 AI106039 · United States
NIAID NIH HHS · AI 29164 · United States
NIAID NIH HHS · AI 36214 · United States
NIAID NIH HHS · AI 38858 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com